Skip to Main Content

Alessandro Santin, MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Contact Information

Alessandro Santin, MD

Office Location

Mailing Address

  • Obstetrics, Gynecology & Reproductive Sciences

    PO Box 208063

    New Haven, CT 06520-8063

    United States

Research Summary

Dr. Santin is a skilled gynecologic oncologist and talented clinical scientist who has a strong background in training and mentoring talented young physician-scientists. Dr. Santin’s research and clinical accomplishments have been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals.

Dr. Santin’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. He is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma. His research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies.

Specialized Terms: Mutational landscape of gynecologic tumors; Therapeutic vaccine development for gynecologic malignancies; Tumor immunology; Immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in gynecologic oncology

Extensive Research Description

Dr. Santin is a skilled gynecologic oncologist and talented clinical scientist who has a strong background in training and mentoring talented young physician-scientists. He has been involved in the training of 15 post-doctoral fellows, including Gynecologic Oncology, Medical Oncology and Surgical Oncology Fellows, the majority of whom have gone on to academic careers in the U.S. and abroad in Gynecologic Oncology and cancer research.

Dr. Santin’s research and clinical accomplishments have been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals. Dr. Santin’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. He is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma.

His research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies. Dr. Santin is an active member of the Gynecologic Oncology Group (GOG) and the International Gynecological Cancer Society (IGCS), the two largest organizations of gynecologic oncologists in the world. He is a member of the GOG Developmental Therapeutics Committee, a national Committee that reviews multi-site concepts/protocols to be implemented at nationwide level by the GOG funded by the NIH and he is Chairman for the entire GOG of multiple Phase II clinical studies testing novel biologic agents in patient harboring gynecologic malignancies.

Dr. Santin has initiated and completed multiple investigator’s initiated FDA approved clinical trials in gynecologic patients using novel immunotherapeutic strategies developed and characterized in his own laboratory. Dr. Santin has been awarded multiple patents for the development of new methods for the early diagnosis of ovarian cancer as well as the development of novel immunotherapeutic methods targeting serine proteases highly expressed in ovarian cancer patients.

Dr. Santin also serves as peer reviewer for a number of journals including Lancet, Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, American Journal of Obstetrics&Gynecology, International Journal of Cancer, British Journal of Cancer, Gynecologic Oncology, International Journal of Radiation Oncology, Obstetrics&Gynecology, Journal of Immunotherapy, International Journal of Gynecological Cancer, Cancer Immunology Immunotherapy, BMC Cancer, Cancer Detection&Prevention, Molecular Cancer Research, Cancer, Cancer Biology & Therapy, Reproductive Sciences.

Coauthors

Research Interests

Genital Neoplasms, Female; Gynecology; Immunotherapy; Neoplasms, Experimental; Ovarian Neoplasms

Selected Publications

Clinical Trials

ConditionsStudy Title
CervixA Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Corpus UteriA Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
OvaryA Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Corpus UteriA Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
CervixA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)
OvaryMIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Other Female GenitalA Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Corpus UteriA Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy
Corpus UteriA Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
Other Female Genital; OvaryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Corpus UteriA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Other Female GenitalA Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Corpus Uteri; Larynx; Lung; Soft Tissue; Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Other Endocrine System; Other Female GenitalEndometrium and Metabolism
Anus; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Kaposi's sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, skin; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Cervix; Urinary BladderNCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
CervixTreatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
Corpus Uteri; Other Female GenitalA Phase II Evaluation of Afatinib